Clinical Trial Update: A 2-Year Study of an Investigational Drug in Obese Patients (0557-011) [Phase 3]

View source ↗

Summary

A 2-year Phase 3 trial of an investigational drug for obesity has completed, with enrollment and status reported; results are not provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Investigational Drug 0557-011

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Obesity | Phase 3 | Status: COMPLETED